Cargando…

Expression and functions of galectin-7 in ovarian cancer

There is a critical need to develop effective new strategies for diagnosis and treatment of ovarian cancer. In the present work, we investigated the expression of galectin-7 (gal-7) in epithelial ovarian cancer (EOC) cells and studied its functional relevance. Immunohistochemical analysis of gal-7 e...

Descripción completa

Detalles Bibliográficos
Autores principales: Labrie, Marilyne, Vladoiu, Maria Claudia, Grosset, Andrée-Anne, Gaboury, Louis, St-Pierre, Yves
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4202155/
https://www.ncbi.nlm.nih.gov/pubmed/25277199
_version_ 1782340265444376576
author Labrie, Marilyne
Vladoiu, Maria Claudia
Grosset, Andrée-Anne
Gaboury, Louis
St-Pierre, Yves
author_facet Labrie, Marilyne
Vladoiu, Maria Claudia
Grosset, Andrée-Anne
Gaboury, Louis
St-Pierre, Yves
author_sort Labrie, Marilyne
collection PubMed
description There is a critical need to develop effective new strategies for diagnosis and treatment of ovarian cancer. In the present work, we investigated the expression of galectin-7 (gal-7) in epithelial ovarian cancer (EOC) cells and studied its functional relevance. Immunohistochemical analysis of gal-7 expression in tissue microarrays showed that while gal-7 was not detected in normal ovarian tissues, positive cytoplasmic staining of gal-7 was detected in epithelial cells in all EOC histological subtypes but was more frequent in high grade tumors and metastatic samples. Gal-7 expression correlated with a significant difference in the overall survival of patients with ovarian serous cystadenocarcinoma. Furthermore, using human EOC cell lines, we found that gal-7 expression was induced by mutant p53. Mechanistically, Matrigel invasion assays and live cell imaging showed that gal-7 increased the invasive behavior of ovarian cancer cells by inducing MMP-9 and increasing cell motility. EOC cells can also secrete gal-7. Recombinant human gal-7 kills Jurkat T cells and human peripheral T cells, suggesting that gal-7 also has immunosuppressive properties. Taken together, our study validates the clinical significance of gal-7 overexpression in ovarian cancer and provides a rationale for targeting gal-7 to improve the outcome of patients with this disease.
format Online
Article
Text
id pubmed-4202155
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-42021552014-10-21 Expression and functions of galectin-7 in ovarian cancer Labrie, Marilyne Vladoiu, Maria Claudia Grosset, Andrée-Anne Gaboury, Louis St-Pierre, Yves Oncotarget Research Paper There is a critical need to develop effective new strategies for diagnosis and treatment of ovarian cancer. In the present work, we investigated the expression of galectin-7 (gal-7) in epithelial ovarian cancer (EOC) cells and studied its functional relevance. Immunohistochemical analysis of gal-7 expression in tissue microarrays showed that while gal-7 was not detected in normal ovarian tissues, positive cytoplasmic staining of gal-7 was detected in epithelial cells in all EOC histological subtypes but was more frequent in high grade tumors and metastatic samples. Gal-7 expression correlated with a significant difference in the overall survival of patients with ovarian serous cystadenocarcinoma. Furthermore, using human EOC cell lines, we found that gal-7 expression was induced by mutant p53. Mechanistically, Matrigel invasion assays and live cell imaging showed that gal-7 increased the invasive behavior of ovarian cancer cells by inducing MMP-9 and increasing cell motility. EOC cells can also secrete gal-7. Recombinant human gal-7 kills Jurkat T cells and human peripheral T cells, suggesting that gal-7 also has immunosuppressive properties. Taken together, our study validates the clinical significance of gal-7 overexpression in ovarian cancer and provides a rationale for targeting gal-7 to improve the outcome of patients with this disease. Impact Journals LLC 2014-07-31 /pmc/articles/PMC4202155/ /pubmed/25277199 Text en Copyright: © 2014 Labrie et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Labrie, Marilyne
Vladoiu, Maria Claudia
Grosset, Andrée-Anne
Gaboury, Louis
St-Pierre, Yves
Expression and functions of galectin-7 in ovarian cancer
title Expression and functions of galectin-7 in ovarian cancer
title_full Expression and functions of galectin-7 in ovarian cancer
title_fullStr Expression and functions of galectin-7 in ovarian cancer
title_full_unstemmed Expression and functions of galectin-7 in ovarian cancer
title_short Expression and functions of galectin-7 in ovarian cancer
title_sort expression and functions of galectin-7 in ovarian cancer
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4202155/
https://www.ncbi.nlm.nih.gov/pubmed/25277199
work_keys_str_mv AT labriemarilyne expressionandfunctionsofgalectin7inovariancancer
AT vladoiumariaclaudia expressionandfunctionsofgalectin7inovariancancer
AT grossetandreeanne expressionandfunctionsofgalectin7inovariancancer
AT gabourylouis expressionandfunctionsofgalectin7inovariancancer
AT stpierreyves expressionandfunctionsofgalectin7inovariancancer